Elicera Therapeutics Secures Chinese Patent Allowance for ELC-401
Swedish clinical-stage immuno-oncology company Elicera Therapeutics said it secured a Chinese patent allowance for ELC-401.
Swedish clinical-stage immuno-oncology company Elicera Therapeutics said it secured a Chinese patent allowance for ELC-401.